Arvinas (ARVN) Return on Capital Employed (2018 - 2026)
Arvinas (ARVN) posted quarterly Return on Capital Employed of 44.76% for Q1 2026, down 3327.0% year-over-year from 1.39% in Q1 2025, and down 141.21% quarter-over-quarter from 18.56% in Q4 2025.
Arvinas (ARVN) Return on Capital Employed (2018 - 2026) Analysis & Trends
Arvinas' Return on Capital Employed history runs 9 years deep, the most recent figure standing at 44.76% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 3327.0% year-over-year to 44.76%; the TTM figure through Mar 2026 stood at 44.76% (down 3327.0% YoY), while the FY2025 annual figure was 15.55%, up 1029.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 44.76%, down from 18.56% in the prior quarter.
- The five-year high for Return on Capital Employed was 11.49% in Q1 2025, with the low at 44.76% in Q1 2026.
- The 5-year median for Return on Capital Employed is 27.83% (2024), against an average of 28.42%.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed soared 2753 bps in 2025, then sank 3327 bps in 2026.
- Arvinas' Return on Capital Employed stood at 26.16% in 2022, then plunged by 66 bps to 43.44% in 2023, then surged by 36 bps to 27.83% in 2024, then surged by 33 bps to 18.56% in 2025, then sank by 141 bps to 44.76% in 2026.
- Business Quant data shows ARVN's Return on Capital Employed at 44.76% in Q1 2026, 18.56% in Q4 2025, and 13.95% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Arvinas | 585.74 Mn | 17.84 Mn | - | -3.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.13% |
| Mar 31, 2026 | -44.76% |
| Dec 31, 2025 | -18.56% |
| Sep 30, 2025 | -13.95% |
| Jun 30, 2025 | -14.87% |
| Mar 31, 2025 | -11.49% |
| Dec 31, 2024 | -27.83% |
| Sep 30, 2024 | -37.72% |
| Jun 30, 2024 | -41.27% |
| Mar 31, 2024 | -39.02% |
| Dec 31, 2023 | -43.44% |
| Sep 30, 2023 | -41.37% |
| Jun 30, 2023 | -36.73% |
| Mar 31, 2023 | -31.23% |
| Dec 31, 2022 | -26.16% |
| Sep 30, 2022 | -20.89% |
| Jun 30, 2022 | -18.05% |
| Mar 31, 2022 | -15.76% |
| Dec 31, 2021 | -14.15% |
| Sep 30, 2021 | -19.12% |